BMS通过与CytomX和Incyte的交易继续推进免疫肿瘤学的发展

Pharmadeals Review Pub Date : 2014-11-06 DOI:10.3833/PDR.V2014I6.2041

Heather Cartwright

{"title":"BMS通过与CytomX和Incyte的交易继续推进免疫肿瘤学的发展","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I6.2041","DOIUrl":null,"url":null,"abstract":"Continuing the high level of deal-making activity seen in the immuno-oncology sector thus far in 2014, Bristol-Myers Squibb (BMS) has formed separate deals with CytomX Therapeutics and Incyte. The deal with CytomX is focused on the discovery, development and commercialisation of masked antibody Probody™ therapies against up to four cancer targets. BMS will also collaborate with Incyte to evaluate its programmed cell death-1 (PD-1) inhibitor nivolumab in combination with Incyte’s INCB24360 in a Phase I/II trial.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2014-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"BMS Continues Immuno-Oncology Push via Deals with CytomX and Incyte\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2014I6.2041\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Continuing the high level of deal-making activity seen in the immuno-oncology sector thus far in 2014, Bristol-Myers Squibb (BMS) has formed separate deals with CytomX Therapeutics and Incyte. The deal with CytomX is focused on the discovery, development and commercialisation of masked antibody Probody™ therapies against up to four cancer targets. BMS will also collaborate with Incyte to evaluate its programmed cell death-1 (PD-1) inhibitor nivolumab in combination with Incyte’s INCB24360 in a Phase I/II trial.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2014I6.2041\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2014I6.2041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

继2014年迄今为止免疫肿瘤领域的高水平交易活动之后，百时美施贵宝(Bristol-Myers Squibb)与巨细胞治疗公司(CytomX Therapeutics)和Incyte分别达成了交易。与巨细胞公司的交易重点是发现、开发和商业化针对多达四种癌症靶点的掩膜抗体Probody™疗法。BMS还将与Incyte合作，在一项I/II期试验中评估其程序性细胞死亡-1 (PD-1)抑制剂nivolumab与Incyte的INCB24360联合使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

BMS Continues Immuno-Oncology Push via Deals with CytomX and Incyte

Continuing the high level of deal-making activity seen in the immuno-oncology sector thus far in 2014, Bristol-Myers Squibb (BMS) has formed separate deals with CytomX Therapeutics and Incyte. The deal with CytomX is focused on the discovery, development and commercialisation of masked antibody Probody™ therapies against up to four cancer targets. BMS will also collaborate with Incyte to evaluate its programmed cell death-1 (PD-1) inhibitor nivolumab in combination with Incyte’s INCB24360 in a Phase I/II trial.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量